Company

Millendo Therapeutics, Inc.

Millendo Therapeutics develops oral drug treatments for cancer.

About

Founded in 2012, Millendo Therapeutics develops oral drug therapies for cancer. Its Amezalpat (TPST-1120) is undergoing pivotal trials for first-line hepatocellular carcinoma in China. The company is based in Ann Arbor, US, and raised USD 47.70 mn in a Series B round led by New Enterprise Associates.

4Funding rounds

11Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in